PMV Pharmaceuticals (NASDAQ:PMVP) Earns Buy Rating from HC Wainwright

PMV Pharmaceuticals (NASDAQ:PMVPGet Free Report)‘s stock had its “buy” rating reiterated by equities research analysts at HC Wainwright in a research report issued on Tuesday, Benzinga reports. They currently have a $5.00 target price on the stock. HC Wainwright’s target price would suggest a potential upside of 134.74% from the company’s previous close.

A number of other research analysts also recently issued reports on PMVP. Craig Hallum assumed coverage on shares of PMV Pharmaceuticals in a research note on Monday. They issued a “buy” rating and a $6.00 price target for the company. Jefferies Financial Group initiated coverage on shares of PMV Pharmaceuticals in a research note on Friday, April 12th. They issued a “buy” rating and a $5.00 price target on the stock.

Get Our Latest Stock Report on PMVP

PMV Pharmaceuticals Price Performance

NASDAQ PMVP opened at $2.13 on Tuesday. PMV Pharmaceuticals has a 1 year low of $1.17 and a 1 year high of $9.72. The company has a market cap of $109.57 million, a price-to-earnings ratio of -1.60 and a beta of 1.56. The stock’s fifty day moving average price is $1.76 and its 200 day moving average price is $1.99.

PMV Pharmaceuticals (NASDAQ:PMVPGet Free Report) last released its quarterly earnings results on Thursday, February 29th. The company reported ($0.31) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.39) by $0.08. Research analysts expect that PMV Pharmaceuticals will post -1.44 earnings per share for the current year.

Institutional Investors Weigh In On PMV Pharmaceuticals

Several hedge funds have recently modified their holdings of the stock. Acadian Asset Management LLC grew its holdings in PMV Pharmaceuticals by 170.7% during the first quarter. Acadian Asset Management LLC now owns 2,080,194 shares of the company’s stock worth $3,533,000 after acquiring an additional 1,311,745 shares during the period. BML Capital Management LLC purchased a new position in shares of PMV Pharmaceuticals in the 1st quarter valued at about $2,221,000. Alkeon Capital Management LLC lifted its stake in shares of PMV Pharmaceuticals by 58.6% in the third quarter. Alkeon Capital Management LLC now owns 2,347,414 shares of the company’s stock valued at $14,413,000 after purchasing an additional 867,547 shares during the period. Vontobel Holding Ltd. boosted its holdings in PMV Pharmaceuticals by 125.8% during the fourth quarter. Vontobel Holding Ltd. now owns 685,985 shares of the company’s stock worth $2,127,000 after buying an additional 382,161 shares in the last quarter. Finally, Sectoral Asset Management Inc. grew its position in PMV Pharmaceuticals by 125.8% during the fourth quarter. Sectoral Asset Management Inc. now owns 685,985 shares of the company’s stock worth $2,127,000 after buying an additional 382,161 shares during the period. 90.20% of the stock is owned by institutional investors and hedge funds.

PMV Pharmaceuticals Company Profile

(Get Free Report)

PMV Pharmaceuticals, Inc, a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function.

See Also

Receive News & Ratings for PMV Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PMV Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.